Grade My Investments
HomeFree Stock Grades › TLSI

TriSalus Life Sciences, Inc. (TLSI) Stock Grade

TLSI · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$343.4M
P/E Ratio
Revenue Growth (YoY)
+53.4%
Net Margin
-86.9%
Return on Equity
115.8%
Dividend Yield
None

About TriSalus Life Sciences, Inc.'s fundamentals

TriSalus Life Sciences is a medical device company with a market capitalization of $343.4 million that is experiencing strong revenue growth of 53.4% year-over-year, indicating expanding sales activity. However, the company is currently unprofitable with a net margin of -86.9% and reported a net loss in its latest annual statement, meaning it is spending significantly more than it generates in revenue. The company does not pay a dividend, which is typical for growth-stage medical device firms that reinvest losses and capital into operations.

Track TLSI free — no credit card required. Live grade + monthly AI report →